Oteseconazole
As of the edition of 20 October 2026, Oteseconazole is a small molecule: marketed, first approved in 2022 (US); US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Vivjoa
- First approved
- 26 April 2022 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Mycovia Pharmaceuticals
- Registered trials
- 10, 0 stopped early
- Disease areas
- Infections; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Immune system; Lungs and airways
US protection
US protection ends in 2036.
The last listed US drug-substance patent ends in 2036. The application that gives this date is held by Mycovia Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product5 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 5 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 2 | 5 | 4 | 1 | 0 |
| Phase 3 | 4 | 3 | 1 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Mycovia Pharmaceuticals | Originator and Lead sponsor of trials | 2018 to now |